Gain Therapeutics Management
Management criteria checks 2/4
Gain Therapeutics' CEO is Gene Mack, appointed in Jun 2024, has a tenure of 1.42 years. total yearly compensation is $1.47M, comprised of 34.1% salary and 65.9% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth $24.34K. The average tenure of the management team and the board of directors is 2.3 years and 5.4 years respectively.
Key information
Gene Mack
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 34.08% |
| CEO tenure | 2yrs |
| CEO ownership | 0.03% |
| Management average tenure | 2.3yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.3 US Biotechs Developing Parkinson’s Therapies
Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients
Summary Gain Therapeutics achieved functional improvement in Parkinson’s patients with GT-02287 in its Phase 1b trial, notably improving MDS-UPDRS Part III motor scores. GT-02287’s mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX’s $66 million market cap is seen as deeply undervalued given positive trial data, large market potential, and higher-value biotech acquisitions. I reiterate a Strong Buy rating for GANX. Read the full article on Seeking AlphaGain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Summary Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson’s disease, with potential for substantial market impact and investor gains. The drug's ability to restore GCase function and its positive preclinical and Phase 1 results highlight its potential as a best-in-class treatment. Gain's aggressive development strategy and strong data sharing indicate confidence, with Phase 1b trial results expected by mid-2025, potentially increasing the company's valuation. Read the full article on Seeking AlphaGain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
Summary Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which had already generated a Phase 3 drug in the past, may be overlooked by investors. Gain Therapeutics is considerably undervalued compared to peers and recent acquisition targets in the neurodegenerative space. Read the full article on Seeking AlphaGain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Summary Gain Therapeutics' drug candidate GT-02287 targets GCase and lysosomal dysfunction, potentially succeeding where others may fail. The company's AI-driven drug discovery engine has generated several targets across different diseases. GT-02287 is currently in a Phase 1 trial for GBA-1-PD, and Gain will add further preclinical data in February to its already interesting preclinical dataset. Gain's stock has been performing well, and similarities with a recent acquisition of Caraway Therapeutics by Merck may confirm its undervaluation. Read the full article on Seeking AlphaGain Therapeutics appoints CEO
Biotechnology company Gain Therapeutics (NASDAQ:GANX) said COO Matthias Alder has been appointed CEO, effective immediately. Alder, who was also appointed to the company's board, succeeds Eric Richman. The size of the company's board is now increased to eight members. Richman will continue to serve as a board member and as a senior advisor. Source: Press ReleaseGain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Gain Therapeutics has a market cap of just $84m. The biotech is developing small molecules to treat rare genetic diseases. The company uses a proprietary drug discovery engine, SEE-Tx, which targets allosteric binding sites, and misfolded proteins - approaches previously validated either by trial data or major investment. Gain has not yet had an IND accepted by the FDA, but targets include GM1 Gangliosidosis, Parkinson's, and Gaucher Disease. There are areas of high unmet need and competitive fields, but Gain does at least have some promising preclinical data. The $7 per share entry point feels cheap to me, with numerous upcoming catalysts, an experienced management team and Board, and oral availability all plus points.Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with multiple value inflections expected. Management has a track record of creating value through pharma partnerships and exits. Approaching top-line data for lead compound in GBA1 Parkinson’s has game-changing potential.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$21m |
| Dec 31 2025 | US$1m | US$500k | -US$20m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | -US$19m |
| Mar 31 2025 | n/a | n/a | -US$21m |
| Dec 31 2024 | US$991k | US$271k | -US$20m |
Compensation vs Market: Gene's total compensation ($USD1.47M) is above average for companies of similar size in the US market ($USD642.98K).
Compensation vs Earnings: Gene's compensation has increased whilst the company is unprofitable.
CEO
Gene Mack (52 yo)
Mr. Gene Mack, M.B.A. is President, Chief Executive Officer & Director of Gain Therapeutics, Inc. from January 06, 2025 and was its Chief Financial Officer since April 8, 2024 until January 06, 2025 and wa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Founder | 9.4yrs | US$93.15k | 2.18% $ 1.6m | |
| President | 2yrs | US$1.47m | 0.034% $ 24.3k | |
| Senior VP of Finance & Principal Financial Officer | 1.4yrs | US$345.07k | 0.079% $ 56.7k | |
| Senior Vice President of Technical Operations | no data | no data | no data | |
| Senior Vice President of Research | 4yrs | no data | no data | |
| Chief Medical Officer | 2.3yrs | no data | no data |
Experienced Management: GANX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Founder | 9.4yrs | US$93.15k | 2.18% $ 1.6m | |
| President | 1.4yrs | US$1.47m | 0.034% $ 24.3k | |
| Independent Director | 5.4yrs | US$80.15k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 5.4yrs | US$63.15k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$76.65k | 0% $ 0 | |
| Independent Director | 7.1yrs | US$78.65k | 0.070% $ 50.7k | |
| Independent Director | 5.4yrs | US$68.15k | 0% $ 0 | |
| Member of Clinical Advisory Board | 1.4yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.4yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.4yrs | no data | no data |
Experienced Board: GANX's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 08:28 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gain Therapeutics, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Raghuram Selvaraju | H.C. Wainwright & Co. |